膀癌中的BCG疗法及其瘤微环境相互作用
Ni Jian1,2, Lei Yu3, Lijuan Ma4
1Synthetic Biology Research Center, Institute for Advanced Study, International Cancer Center of Shenzhen University, Shenzhen, China.
Clinical microbiology reviews
|March 20, 2025
概括
巴西勒斯卡尔梅特-盖林 (BCG) 免疫疗法是膀癌的标准,但面临抗药性和副作用. 这篇评论探讨了BCG的研究.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 微生物学 微生物学
背景情况:
- 30多年来,Bacillus Calmette-Guérin (BCG) 已经成为非肌肉侵入性膀癌 (NMIBC) 治疗的黄金标准.
- 尽管它有效,但挑战包括不清楚的机制,30-50%的抗药率和显著的副作用.
- 了解BCG与瘤微环境和膀微生物群的相互作用至关重要.
研究的目的:
- 为提供关于BCG在膀癌中的抗瘤机制的最新讨论.
- 分析目前关于BCG耐药性的研究,并探索改进BCG基础免疫疗法的策略.
- 为开发瘤学新型细菌疗法提供见解.
主要方法:
- 对BCG的抗瘤机制和耐药性的临床前和临床研究的审查.
- 分析BCG与膀癌细胞和瘤微环境的相互作用.
- 纳入最近关于BCG和膀微生物组的研究.
主要成果:
- BCG通过瘤微环境中的直接作用和相互作用来发挥抗瘤作用.
- 在膀癌中已经确定了对BCG的内在和适应性耐药机制.
- 新兴的策略包括重组BCG,组合疗法,优化方案和微生物组向.
结论:
- 改善BCG免疫疗法需要解决耐药性,减少毒性和提高疗效.
- 准膀微生物组提供了一个新的治疗途径.
- 来自BCG的经验教训将为未来癌症治疗的细菌疗法的发展提供信息.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


